Carolyn Keever-Taylor, Ph.D.
Director, Blood and Marrow Transplantation Processing Laboratories
Dr. Carolyn Keever-Taylor has is a recognized expert in the field of Cellular Therapy with over 100 full length publications, including journal articles and book chapters. She is an active in a number of professional societies including the American Society for Hematology (ASH) the International Society for Cellular Therapy (ISCT) the American Society for Blood and Marrow Transplantation(ASBMT) and the World Wide Network for Blood and Marrow Transplantation (WBMT) where she has served on various committees, advisory boards, and executive boards. Dr. Keever-Taylor has also participated actively in the Foundation for the Accreditation of Cellular Therapy (FACT) since its founding in 1996 to set standards, perform inspections, and provide education for inspectors and programs. She currently serves as the FACT Vice President. She additionally serves on the steering committees of several multi-center clinical trials involving novel methods of cellular therapy product processing or use of such products for new indications.
Dr. Keever-Taylor's primary research interests have been focused on immune reconstitution after BMT and the use of immunotherapy to improve transplant outcomes. She has been a principle or co-investigator on several protocols conducted under investigational new drug (IND) approvals. The most recent project uses cytotoxic T cell lines from transplant donors prepared in the laboratory to recognize common viral pathogens (EBV, CMV, Adenovirus) that cause considerable morbidity and mortality in BMT patients who have not yet recovered a fully functioning immune system.
Book Chapters (last 10 yrs)
1. Keever-Taylor CA. Immune reconstitution following allogeneic transplantation. Second Edition In: Soiffer RJ, ed: Hematopoietic Stem Cell Transplantation, Humana Press Inc, Totowa, pp377-420, 2008
2. Keever-Taylor CA. Standards and Accreditation. In Aremen E, Szczepiorkowski Z, et al eds: Cellular Therapy: Principles, Methods and Regulations. Chapter 7, Bethesda, AABB, pp 56-66, 2009.
3. Keever-Taylor CA. Description and Procedures for Performing White Blood Cell Counts and Differentials on Cellular Therapy Products. In Aremen E, Szczepiorkowski Z, et al eds: Cellular Therapy: Principles, Methods and Regulations, Assessment and Characterization of Cell Therapy Products: Enumeration, Identity, Purity and Potency. Chapter 44, Bethesda, AABB, pp 528-537, 2009.
Peer-Reviewed Journal Articles (last 10 years)
1. Ramadan G, Konings S, Kurup VP, Keever-Taylor CA. Generation of Aspergillus- and CMV-Specific T cell responses using autologous fast-dendritic cells (Fast-DC). Cytotherapy, 6:223-234, 2004.
2. Hsu KC, Keever-Taylor CA, Pinto C, Heller G, Wilton A, Arkun K, Horowitz H, O’Reilly R, Dupont B. Improved outcome in allogeneic hematopoietic stem cell transplantation in acute myelogenous leukemia (AML) predicted by donor KIR genotype and recipient HLA genotype in T-cell depleted HLA identical sibling transplants. Blood:105:4878-4884:2005
3. Ramadan G, Davies B, Kurup VP, Keever-Taylor CA. Generation of Th1 T cell responses directed to a HLA Class II restricted epitope from the Aspergillus f16 allergen. Clin Exp Immunol, 139:257-267, 2005.
4. Ramadan G, Davies B, Kurup VP, Keever-Taylor CA. Generation of cytotoxic T cell responses directed to HLA Class I restricted epitopes from the Aspergillus f16 allergen. Clin Exp Immunol, 140:81-91, 2005.
5. McGregor DK, Keever-Taylor CA, Schur Bernard, Vesole DH, Bredeson C, Logan B, Farkas DH, Chang CC. The implication of follicular lymphoma patients receiving allogeneic stem cell transplantation from donors carrying t(14;18) positive cells. Bone Marrow Transplant:35:1049-1054, 2006.
6. Talano JA, Casper JT, Camitta BM, Keever-Taylor CA, Murray KJ, Eapen M, Pierce KL, Margolis DA. Alternative Donor Bone Marrow Transplant for Children with Philadelphia Chromosome ALL. Bone Marrow Transplant 37:135-141, 2006.
7. Keever-Taylor CA, Browning MB, Johnson BD, Truitt RL, Bredeson CN, Behn B, Tsao A. Rapamycin Enriches for CD4+CD25+CD27+Foxp3+ Regulatory T cells in ex vivo Expanded CD25-enriched Products From Healthy Donors and Patients with Multiple Sclerosis. Cytotherapy 9:144-157, 2007
8. Zhu F, Ramadan G, Davies B, Margolis DA, Keever-Taylor CA. Stimulation by means of dendritic cells followed by Epstein-Barr virus transformed B cells as antigen presenting cells is more efficient that dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T-cell response. Clin Exp Immunol 151:284-296, 2008.
9. Huang WT, Yang X, Zhou X, Monzon F, Hagenkord JM, Wu LY, Keever-Taylor C, Novoa-Takara L, Wong TC, Young K, Chang CC. Multiple distinct clones co-exist in different lineages in myelodysplastic syndromes revealed by flow cytometry sorting and single nucleotide polymorphism microarray analysis. Leuk Res 33:847-853, 2009.
10. Drobyski WR, Hari P, Keever-Taylor C, Komorowski R, Grossman W. Severe Autologous GVHD After Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma. Bone Marrow Transplant: 43, 169-177, 2009.
11. Conway EJ, Wen J, Feng Y, Hunag WT, Mo A, Hari P, Keever-Taylor CA, Vesole DH, Chang CC. Phenotyping studies of clonotypic B-lymphocytes from patients with multiple myeloma by flow cytometry. Arch Path Lab Med:133:1594-1599, 2009.
12. Filicko-O'Hara J, Grosso D, Flomenberg PR, Friedman TM, Brunner J, Drobyski W, Ferber A, Kakhniashvili I, Keever-Taylor C, Mookerjee B, Talano JA, Wagner JI, Korngold R, Flomenberg N. Antiviral responses following L-leucyl-L-leucine methyl esther (LLME)-treated lymphocyte infusions: graft-versus-infection without graft-versus-host disease. Biol Blood Marrow Transplant 15: 1609-1619, 2009.
13. Keever-Taylor CA, Wagner JE, Kernan NA, Small TN, Carter SL, Thompson JS, Cloud GA, Lamb LS. Comparison of immune recovery in recipients of unmanipulated vs T-cell-depleted grafts from unrelated donors in a multicenter randomized phase II-III trial (T-cell depletion trial). Bone Marrow Transplant:45, 587-589, 2010.
14. Collins NH, Gee AP, Durett AG, Fangyu K, Zhang M-J, Champlin RE, Confer D, Eapen M, Howard A, King R, Laughlin MJ, Plante RJ, Setterholm M, Spellman S, Keever-Taylor C, Wagner JE, Weisdorf DJ. The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplant outcome. Biol Blood Marr Transplant:16, 253-262, 2010.
15. Zhu F, Xu H, Tsao A, Margolis DA, Keever-Taylor CA. Generation of Cytotoxic T Cell Lines Using Overlapping Pentadecapeptides Derived from Conserved regions of the Adenovirus Hexon Protein. J Gen Virology 91:1577-1589, 2010
16. Devine SM, Soiffer RJ, Pasquini M, Carter S, Hari P, McCants K, Stein A, Lazarus HM, Linker C, Stadtmauer EA, Keever-Taylor CA, O'Reilly RJ. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marr Transplant:17. 1343-1351, 2011.
17. Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini M, Hari P, Stein A, Lazarus HM, Linker C, Goldstein SC, Stadtmauer EA , O'Reilly RJ. Characteristics of CD34-Enriched Products Processed at Multiple Centers Using the CliniMACS System- Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303, Biol Blood Marrow Transplant 18:690-697. 2012.
18. Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus H, Applebaum FR, Keever-Taylor CA, Horowist MA, Carter SL, O’Reilly RJ, Soiffer RJ. Comparative Outcomes of Donor Graft CD34+ Selection and Immune Suppressive Therapy as Graft-vs-Host Disease Prophylaxis for Patients with Acute Myeloid Leukemia in Complete Remission undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation, JCO: 30, 3194-3201, 2012.
19. Leemhuis T, Padley D, Keever-Taylor C, Niederwieser D, Teshima T, Lanza F, Chabannon C, Szaboics P, Bazarbachi A, Koh M, on behalf of the Graft Processing Subcommittee of the Worldwide Network for Blood and Bone Marrow Transplantation (WBMT). Essential Requirements for Setting Up a Stem Cell Processing Laboratory. Bone Marrow Transplant, In Press, 2014.
20. Törlén J, Ringdén O, Le Rademacher J, Batiwalla M, Chen J, Erkers T, Ho V, Kebriaei P, Keever-Taylor C, Kindwall-Keller T, Lazarus H, Laughlin MJ, Lill M, O’Brien T, Perales MA, Rocha V Savani BN, Szwajcer D, Valcarcel D and Eapen M. Low CD34 dose is associated with survival after reduced intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. Blood, submitted, 2014.